m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00678)
Target Name Ly6/PLAUR domain-containing protein 1 (LYPD1)
Synonyms
Putative HeLa tumor suppressor; PHTS
    Click to Show/Hide
Gene Name LYPD1
Chromosomal Location 2q21.2
Function
Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety.
    Click to Show/Hide
Gene ID 116372
Uniprot ID
LYPD1_HUMAN
HGNC ID
HGNC:28431
Ensembl Gene ID
ENSG00000150551
KEGG ID
hsa:116372
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
LYPD1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5
Cell Line 143B cell line Homo sapiens
Treatment: siALKBH5 transfected 143B cells
Control: siControl 143B cells
 GSE154528
Regulation
logFC: 7.22E-01
p-value: 3.53E-02
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary ALKBH5 suppressed the proliferation and invasion capabilities of HCC cells in vitro and in vivo. Mechanistically, ALKBH5-mediated m6A demethylation led to a post-transcriptional inhibition of Ly6/PLAUR domain-containing protein 1 (LYPD1).
Target Regulation Down regulation
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12.02
 Disease Info 
In-vitro Model SMMC-7721 Endocervical adenocarcinoma Homo sapiens CVCL_0534
PLC/PRF/5 Adult hepatocellular carcinoma Homo sapiens CVCL_0485
MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Hep 3B2.1-7 Childhood hepatocellular carcinoma Homo sapiens CVCL_0326
HCCLM3 Adult hepatocellular carcinoma Homo sapiens CVCL_6832
BEL-7402 Endocervical adenocarcinoma Homo sapiens CVCL_5492
Liver cancer [ICD-11: 2C12]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary ALKBH5 suppressed the proliferation and invasion capabilities of HCC cells in vitro and in vivo. Mechanistically, ALKBH5-mediated m6A demethylation led to a post-transcriptional inhibition of Ly6/PLAUR domain-containing protein 1 (LYPD1).
Responsed Disease Hepatocellular carcinoma [ICD-11: 2C12.02]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Down regulation
In-vitro Model SMMC-7721 Endocervical adenocarcinoma Homo sapiens CVCL_0534
PLC/PRF/5 Adult hepatocellular carcinoma Homo sapiens CVCL_0485
MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
Hep 3B2.1-7 Childhood hepatocellular carcinoma Homo sapiens CVCL_0326
HCCLM3 Adult hepatocellular carcinoma Homo sapiens CVCL_6832
BEL-7402 Endocervical adenocarcinoma Homo sapiens CVCL_5492
References
Ref 1 ALKBH5 suppresses malignancy of hepatocellular carcinoma via m(6)A-guided epigenetic inhibition of LYPD1. Mol Cancer. 2020 Aug 10;19(1):123. doi: 10.1186/s12943-020-01239-w.